Browsing by Author "Pascual, Tomás"
Now showing items 1-10 of 10
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Pascual, Tomás; Martin, Miguel; Fernández-Martínez, Aranzazu; Alba, Emilio; Rodríguez-Lescure, Álvaro; Cortés Castan, Javier; Paré, Laia (Frontiers Media, 2019-04-26) -
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Schettini, Francesco; Chic, Nuria; Brasó-Maristany, Fara; Pascual, Tomás; Conte, Benedetta; Peg Camara, Vicente; Fasani, Roberta; Paré, Laia (Nature Research, 2021-01-04) -
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Prat, Aleix; GUARNERI, VALENTINA; Brasó Maristany, Fara; Sanfeliu Torres, Esther; Paré, Laia; Cortés Castan, Javier; Pascual, Tomás; Vivancos, Ana (Elsevier, 2022-01) -
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
Griguolo, Gaia; Pascual, Tomás; Fasani, Roberta; Chic, N.; Antunes de Melo Oliveira, Ana Mafalda; Nuciforo, Paolo Giovanni; Serna, Garazi; Guardia, Xavier (Nature Research, 2021-03-19) -
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
Pascual, Tomás; Antunes de Melo Oliveira, Ana Mafalda; Villagrasa, Patricia; Ortega Cebrian, Vanesa; Bermejo, Begoña; Nuciforo, Paolo Giovanni; Rubio Rodríguez, Isabel Teresa; Cortés Castan, Javier; Paré, Laia (Nature Research, 2021-11-25) -
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
Adamo, Barbara; Pascual, Tomás; Vidal, Maria; Pérez Fidalgo, José A; Gómez Pardo, Patricia; Paré, Laia; Bellet Ezquerra, Meritxell (Springer Nature, 2019-09-18) -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Brasó-Maristany, Fara; Griguolo, Gaia; Pascual, Tomás; Nuciforo, Paolo Giovanni; Llombart-Cussac, Antonio; Antunes de Melo Oliveira, Ana Mafalda; Paré, Laia (Nature Research, 2020-01-20) -
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
Fernandez-Martinez, Aranzazu; Pascual, Tomás; Singh, Baljit; Nuciforo, Paolo; Rashid, Naim U.; Ballman, Karla (American Medical Association, 2023-04) -
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
Gavilá Gregori, Joaquín; Antunes de Melo Oliveira, Ana Mafalda; Pascual, Tomás; Pérez García, José; Gonzàlez, Xavier; Canes, Jordi (BMC, 2019-01-09) -
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
Pascual, Tomás; Antunes de Melo Oliveira, Ana Mafalda; Ciruelos, Eva; Gavilá Gregori, Joaquín; Espinosa Bravo, Martin; Arumí De Dios, Míriam; Bellet Ezquerra, Meritxell; Saura Manich, Cristina (Frontiers Media, 2021-04)